Pyxis Oncology (PYXS) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 157.4% versus a loss of 31.6%. Over five years, PYXS leads with a -83.1% price change compared with -92.5% for QTTB. Q32 Bio is the larger company by market cap ($248.3 million vs $242.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | QTTB |
|---|---|---|
| Share price | $2.03 | $8.34 |
| Market cap | $242.50M | $248.28M |
| 1-day change | +2.01% | +3.09% |
| YTD return | +73.04% | +151.20% |
| 1-year return | -31.62% | +157.41% |
| 5-year return | -83.09% | -92.53% |
| P/E ratio (TTM) | — | 2.57 |
| EPS (TTM) | $-1.40 | $3.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $23.57 |
| 52-week low | $1.03 | $1.91 |
| Distance from 52-week high | -63.42% | -64.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +327.09% | +374.82% |
| Average volume | 1.26M | 1.38M |
| Shares outstanding | 119.46M | 29.77M |
| Employees | 56 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed PYXS by 189.0 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
PYXS vs QTTB FAQ
Which is bigger, Pyxis Oncology or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $248.28M compared with $242.50M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or QTTB?
QTTB returned +157.41% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.